– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs.

Calliope is a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the safety, tolerability and pharmacokinetics of orally administered TP-05 in approximately 700 healthy adults at risk for Lyme disease across endemic regions of the United States. Tarsus plans to complete enrollment during the 2026 tick season, with topline results expected in the first half of 2027.